

## CORRECTION

[View Article Online](#)  
[View Journal](#) | [View Issue](#)



Cite this: *Biomater. Sci.*, 2023, **11**, 4397

## Correction: Effectiveness of a novel gene nanotherapy based on putrescine for cancer treatment

Sainza Lores,<sup>a,b</sup> Manuel Gámez-Chiachio,<sup>c,d</sup> María Cascallar,<sup>a,b,d</sup> Carmen Ramos-Nebot,<sup>c,d</sup> Pablo Hurtado,<sup>d,e</sup> Sandra Alijas,<sup>a,e</sup> Rafael López López,<sup>a,b,d,e</sup> Roberto Piñeiro,<sup>d,e</sup> Gema Moreno-Bueno<sup>\*c,d,f</sup> and María de la Fuente<sup>\*a,b,d,g</sup>

DOI: 10.1039/d3bm90029k  
[rsc.li/biomaterials-science](http://rsc.li/biomaterials-science)

Correction for 'Effectiveness of a novel gene nanotherapy based on putrescine for cancer treatment' by Sainza Lores *et al.*, *Biomater. Sci.*, 2023, <https://doi.org/10.1039/d2bm01456d>.

The authors regret the omission of a grant number in their acknowledgements section. The corrected acknowledgements section is as shown below.

This research was funded by Instituto de Salud Carlos III (ISCIII) and the European Regional Development Fund (FEDER) (grant numbers: CB16/12/00328, PI18/00176; AC18/00045; CIBERONC; CB16/12/00295), by ERA-NET EURONANOMED III project METASTARG (grant number JTC2018-045), by Roche-Chus Joint Unit, Axencia Galega de Innovación (GAIN), Consellería de Economía, Emprego e Industria (IN853B 2018/03, IN607B2021/14), and GAIN grant by the Spanish Ministry of Economy and Innovation (PID2019-104644RB-I00), and by the AECC Scientific Foundation (FC\_AECC PROYE19036MOR). S. L. and P. H. also acknowledge the funding given by GAIN (IN606A-2019/003 and IN606A-2018/019). G. M. B. thanks the financial support given. We gratefully thank Raquel Antón Segurado for her technical support in scanning transmission electron microscopy, Montserrat García Lavandeira and Marta Picado for their technical support with confocal imaging, Lidia Martínez and Saleta Morales for their technical support with cell culture maintenance and treatment, and all the co-workers in our laboratories for the help and discussion day by day. Funding for open access charge: Universidade de Santiago de Compostela/CISUG.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup>Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain. E-mail: [sainza.lores@gmail.com](mailto:sainza.lores@gmail.com), [maria.cascallarc@gmail.com](mailto:maria.cascallarc@gmail.com), [maria.fuente.freire@sergas.es](mailto:maria.fuente.freire@sergas.es); Tel: +34-981-955-706

<sup>b</sup>Universidade de Santiago de Compostela (USC), Praza do Obradoiro, s/n, Santiago de Compostela, 15782 A Coruña, Spain

<sup>c</sup>Translational Cancer Research Laboratory, Department of Biochemistry, Autonomous University of Madrid, School of Medicine, "Alberto Sols" Biomedical Research Institute CSIC-UAM, IdiPaz, Arturo Duperier 4, 28029 Madrid, Spain. E-mail: [mgomez@iib.uam.es](mailto:mgomez@iib.uam.es), [cramos@iib.uam.es](mailto:cramos@iib.uam.es), [gmoreno@iib.uam.es](mailto:gmoreno@iib.uam.es)

<sup>d</sup>Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain

<sup>e</sup>Roche-CHUS Join Unit. Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain. E-mail: [felurh@gmail.com](mailto:felurh@gmail.com), [sandraalijasperez@gmail.com](mailto:sandraalijasperez@gmail.com), [rafa.lopez.lopez@gmail.com](mailto:rafa.lopez.lopez@gmail.com), [Roberto.Pineiro.Cid@sergas.es](mailto:Roberto.Pineiro.Cid@sergas.es)

<sup>f</sup>MD Anderson International Foundation, Gómez Hemans s/n, 28033 Madrid, Spain

<sup>g</sup>DIVERSA Technologies SL, Edificio Emprendia, Universidad de Santiago de Compostela, Campus Vida s/n, 15782 Santiago de Compostela, Spain

